Delta Asset Management’s Fortress Biotech FBIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-400
Closed -$1.74K 687
2023
Q3
$1.74K Hold
400
﹤0.01% 599
2023
Q2
$3.3K Buy
+400
New +$3.96K ﹤0.01% 556
2019
Q1
Sell
-400
Closed -$5K 574
2018
Q4
$5K Buy
400
+67
+20% +$1.12K ﹤0.01% 511
2018
Q3
$8K Hold
333
﹤0.01% 486
2018
Q2
$15K Hold
333
﹤0.01% 394
2018
Q1
$23K Hold
333
﹤0.01% 323
2017
Q4
$20K Hold
333
﹤0.01% 344
2017
Q3
$22K Hold
333
﹤0.01% 305
2017
Q2
$24K Hold
333
﹤0.01% 298
2017
Q1
$19K Hold
333
﹤0.01% 337
2016
Q4
$14K Hold
333
﹤0.01% 370
2016
Q3
$15K Hold
333
﹤0.01% 355
2016
Q2
$13K Hold
333
﹤0.01% 379
2016
Q1
$16K Hold
333
﹤0.01% 351
2015
Q4
$14K Hold
333
﹤0.01% 371
2015
Q3
$13K Hold
333
﹤0.01% 374
2015
Q2
$17K Hold
333
﹤0.01% 354
2015
Q1
$19K Hold
333
﹤0.01% 350
2014
Q4
$12K Hold
333
﹤0.01% 400
2014
Q3
$11K Hold
333
﹤0.01% 400
2014
Q2
$9K Hold
333
﹤0.01% 423
2014
Q1
$10K Hold
333
﹤0.01% 411
2013
Q4
$13K Hold
333
﹤0.01% 383
2013
Q3
$35K Hold
333
0.01% 257
2013
Q2
$43K Buy
+333
New +$49.1K 0.01% 231

Other funds holding FBIO

Delta Asset Management's FBIO Position: Q4 2023 in Review

Delta Asset Management sold out of Fortress Biotech (FBIO) in Q4 2023, closing a stake of 400 shares — an estimated $1.74K sold.

Delta Asset Management first reported a position in FBIO in Q2 2013 and held it in 25 quarters. The position peaked at $43K in Q2 2013. 42 funds tracked by Wall St. Rank hold FBIO as of Q4 2023.

  • Delta Asset Management reported no remaining Fortress Biotech position as of Q4 2023 after selling out during the quarter.
  • Delta Asset Management sold 400 Fortress Biotech shares in Q4 2023, an estimated $1.74K.
  • Delta Asset Management first reported a position in Fortress Biotech in Q2 2013 and held it in 25 quarters.
  • Delta Asset Management's Fortress Biotech position peaked at $43K in Q2 2013.
  • 42 funds tracked by Wall St. Rank held Fortress Biotech as of Q4 2023.

Based on Delta Asset Management's 13F filing for Q4 2023, filed 9 Feb 2024.